Oakmark International Strategy Q4 2025 New Investments And Divestments [Seeking Alpha]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Seeking Alpha
We initiated the following position(s) during the period AstraZeneca, IMCD, Sanofi, Symrise and Unilever. We eliminated the following position(s) during the period Exor, Komatsu, Mercedes-Benz Group, Novartis, Sandvik, Schroders, SKF CI B and Worldline. Sargis Zubov/iStock via Getty Images The following segment was excerpted from the Oakmark International Strategy Q4 2025 Commentary. Portfolio Positioning We initiated the following position(s) during the period: AstraZeneca ( AZN ) is one of the largest pharmaceutical companies in This article was written by Quick Insights AZN was purchased due to its robust on-market portfolio, sector-leading pipeline, and strong management, with recent regulatory concerns providing an attractive entry below intrinsic value. IMCDY's technical salesforce, global scale, and pricing power in specialty chemicals, combined with substantial M&A opportunities, support a thesis for long-term re-rating as market fears subside. UL's new
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Press Release: Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemiaGlobeNewswire
- Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Why OpenAI's drug royalties deal won't work [Yahoo! Finance]Yahoo! Finance
- Pfizer sets sights on R&D strategy amid modest FY25 results [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 2/6/26 - Form 6-K
- 2/5/26 - Form S-8
- 1/29/26 - Form 6-K
- SNY's page on the SEC website